TICKERNERD
Menu
TLSATLSAHealthcare · Biotechnology

TLSA Stock Forecast: Tiziana Life Sciences Ltd. (Bermuda) Price Predictions for 2026-2027

Last close, 11 Sept 2026
$0.96
0.00% on the day

The 2 Wall Street analysts covering Tiziana Life Sciences Ltd. (Bermuda) hold a median 12-month price target of $8.04 — +737.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$122.2M
Ticker Nerd rank
23 / 100
Median analyst target
$8.04
Analysts covering
2
Total return, dividends reinvested
1W
−1.0%
1M
−5.0%
YTD
−35.6%
1Y
−46.4%
From 52W high
−58.1%
From 52W low
+7.9%
$0.89
$2.29
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TLSA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tiziana Life Sciences Ltd. (Bermuda) on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
23 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
73
Accruals
72
Volatility
64
Revisions
49
Value
45
Issuance
23
Growth
22
Quality
10
Momentum
10

Size (73): Smaller than most of the companies we track.

Momentum (10): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TLSA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TLSA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26TLSAHigh $9.06Median $8.04Low $7.01

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $7.01Median $8.04High $9.06

The green dot is the last close — the median target sits +737.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Sept 2026BTIGInitiatesBuy$7.00
6 Sept 2022ThinkEquityInitiatesBuy—
13 June 2022ThinkEquityInitiatesBuy—
12 Apr 2021Zacks Investment ResearchInitiatesNot Rated—
21 Sept 2020HC Wainwright & Co.MaintainsBuy$25 → $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TLSA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TLSA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Tiziana Life Sciences Ltd. (Bermuda) returned −46.4% against +17.5% for the S&P 500, dividends included.

TLSA vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26TLSAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TLSA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Tiziana Life Sciences Ltd. (Bermuda) (TLSA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.9×

Cheaper than 91% of US stocks

Price / sales
—
Price / book
14.4×

Cheaper than 6% of US stocks

EV / EBITDA
−5.3×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−924.3%

Higher than 2% of US stocks

Return on assets
−116.0%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Tiziana Life Sciences Ltd. (Bermuda) (TLSA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tiziana Life Sciences Ltd. (Bermuda) has a market value of $122.2M and an enterprise value of $112.1M.

  • Shares outstanding: 120.5M.

  • Trailing P/E: −5.9×; forward P/E: −4.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Tiziana Life Sciences Ltd. (Bermuda) employs 10 people.

market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

TLSA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TLSATiziana Life Sciences Ltd. (Bermuda)$122.2M
23
BMEABiomea Fusion, Inc.$123.0M
52
MISTMilestone Pharmaceuticals, Inc.$122.0M
16
HURATuHURA Biosciences, Inc.$124.5M
19
OKUROnKure Therapeutics, Inc.$125.2M
52
VTVTvTv Therapeutics, Inc.$125.9M
77
CBUSCibus, Inc.$119.6M
36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tiziana Life Sciences Ltd. (Bermuda) — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TLSA news & analysis

Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration

Proactive Investors · 3 Sept 2026positive

BTIG initiated coverage on Tiziana Life Sciences with a Buy rating and a $7 price target, citing the company's approach to modulating central nervous system inflammation via foralumab, an anti-CD3 antibody delivered as a nasal spray to stimulate regulatory T-cell production and reduce neurodegeneration-driving inflammation.

Why it matters — A positive analyst rating from BTIG highlights growing external recognition of Tiziana's foralumab-based strategy for treating neurodegenerative disease.

Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026

Proactive Investors · 24 Aug 2026neutral

Tiziana Life Sciences announced it will present a poster on its Phase 2a BANYAN clinical trial of intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday. The presentation, titled "Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch Trial," is scheduled for 4:30-6:30 pm Eastern Time during the Scientific Poster Session.

Why it matters — The presentation gives TLSA watchers an update on the progress and public visibility of its Phase 2a foralumab trial in ALS.

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

GlobeNewsWire · 24 Aug 2026positive

Tiziana Life Sciences announced that a poster on its Phase 2a BANYAN clinical trial of intranasal foralumab, part of the Healey ALS MyMatch trial, will be presented by Dr. Pinar Uysal on August 24, 2026, during a scientific poster session at ALS Nexus 2026 in Orlando, Florida.

Why it matters — The presentation increases visibility of Tiziana's lead intranasal foralumab candidate within the ALS research community.

Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition

Benzinga · 31 July 2026positive

Tiziana Life Sciences announced quantitative PET imaging results from the third patient in its Phase 2 clinical trial, indicating a reduction in neuroinflammation for a rare neurodegenerative condition.

Why it matters — A TLSA watcher would care because these imaging results represent progress in the company's clinical development for a rare neurodegenerative disease.

Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient

Proactive Investors · 31 July 2026positive

Tiziana Life Sciences reported imaging results from the third multiple system atrophy (MSA) patient to complete dosing in its Phase 2 trial of intranasal foralumab, with PET scans showing reductions in brain inflammation in regions commonly affected by MSA.

Why it matters — This is the third MSA patient to show reduced brain inflammation on treatment, suggesting a potential pattern of clinical benefit that could support the therapeutic promise of intranasal foralumab for this neurodegenerative disease.

FAQ

Frequently asked questions about TLSA stock

What is the TLSA stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Tiziana Life Sciences Ltd. (Bermuda) have a median 12-month price target of $8.04, with estimates ranging from $7.01 to $9.06. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TLSA stock a buy right now?

Of the 2 analysts covering Tiziana Life Sciences Ltd. (Bermuda), 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tiziana Life Sciences Ltd. (Bermuda) 23 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TLSA?

As at 12 Sept 2026, Tiziana Life Sciences Ltd. (Bermuda) ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (73 of 100).

Will TLSA stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +737.0% from the last close, and Ticker Nerd's factor model ranks Tiziana Life Sciences Ltd. (Bermuda) 23 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TLSA stock forecast for 2030?

No analyst covering Tiziana Life Sciences Ltd. (Bermuda) publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TLSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7.01 to $9.06 over the next 12 months.

How has TLSA stock performed over the past year?

Tiziana Life Sciences Ltd. (Bermuda) returned -46.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tiziana Life Sciences Ltd. (Bermuda) do?

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company focused on developing immunotherapy-based treatments for neurodegenerative, neuroinflammatory, and lung diseases. Its current pipeline centers on candidates such as intranasal Foralumab, a fully human anti-CD3 monoclonal antibody being studied for conditions including secondary progressive multiple sclerosis, Alzheimer’s disease, amyotrophic lateral sclerosis, and other central nervous system disorders.

What is the latest news on TLSA?

The most recent item we track (Proactive Investors, 3 Sept 2026): "Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration". BTIG initiated coverage on Tiziana Life Sciences with a Buy rating and a $7 price target, citing the company's approach to modulating central nervous system inflammation via foralumab, an anti-CD3 antibody delivered as a nasal spray to stimulate regulatory T-cell production and reduce neurodegeneration-driving inflammation.

Company

About Tiziana Life Sciences Ltd. (Bermuda).

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company focused on developing immunotherapy-based treatments for neurodegenerative, neuroinflammatory, and lung diseases. Its current pipeline centers on candidates such as intranasal Foralumab, a fully human anti-CD3 monoclonal antibody being studied for conditions including secondary progressive multiple sclerosis, Alzheimer’s disease, amyotrophic lateral sclerosis, and other central nervous system disorders. The company is also advancing additional programs, including TZLS-501, an anti-IL-6R antibody aimed at inflammatory pathways, and Milciclib, an oncology candidate evaluated in solid tumors and related cancer indications. Tiziana Life Sciences uses alternative drug delivery approaches, including nasal, oral, and inhalation routes, to support localized immunotherapy and broaden treatment options across autoimmune, inflammatory, and cancer-related markets.

CEO Dr. Ivor R. Elrifi Ph.D. · 10 employees · United Kingdom · https://www.tizianalifesciences.com